Clinicians often encounter unexpected adrenal masses during routine abdominal imaging. However, managing these findings effectively requires strict adherence to adrenal incidentaloma management guidelines to avoid missing functional or malignant lesions. A recent retrospective study conducted at a tertiary hospital in New Zealand highlights significant gaps in following international recommendations. Specifically, the audit revealed that only a small fraction of patients received the recommended biochemical and radiological follow-up.

Adhering to Adrenal Incidentaloma Management Guidelines

The study evaluated over 10,000 consecutive computed tomography (CT) scans and identified 143 incidentalomas. Unfortunately, less than half of these cases followed the American College of Radiology (ACR) imaging recommendations. Adherence to the European Society of Endocrinology (ESE) biochemical screening guidelines was even lower, at approximately 15%. Consequently, many patients may remain at risk for undetected hormonal excess because they do not receive standardized care.

Furthermore, patient-related factors significantly influenced follow-up completion. Researchers found that older adults were nearly three times less likely to complete recommended screenings compared to younger patients. In contrast, individuals with larger lesions—specifically those over 4 cm—showed higher adherence rates. This discrepancy suggests that clinicians may prioritize larger masses while potentially overlooking the functional risks associated with smaller lesions.

The Role of Specialized Referral and Integrated Clinics

One of the most striking findings was the impact of endocrinology referrals. Patients referred to specialist care demonstrated an 81.8% adherence rate to guidelines, compared to just 12.1% for those managed by other services. Therefore, establishing integrated adrenal incidentaloma clinics could streamline the diagnostic pathway. Moreover, adopting non-washout imaging protocols could reduce the burden on radiology departments. The study estimated that this approach alone would have saved 80 scans in the evaluated cohort. Ultimately, standardized pathways improve both clinical outcomes and the overall patient experience.

Frequently Asked Questions

What are the primary goals of adrenal incidentaloma management?

The main objectives are to exclude malignancy and identify hormonal hypersecretion, such as pheochromocytoma, primary aldosteronism, or Cushing's syndrome.

How does lesion size influence follow-up?

Lesions greater than 4 cm generally carry a higher risk of malignancy and require more rigorous monitoring or surgical evaluation. However, smaller lesions also require biochemical screening to rule out functional activity.

Why is a multidisciplinary approach recommended?

A multidisciplinary team, involving endocrinologists, radiologists, and surgeons, ensures that patients receive comprehensive evaluation and adhere to evidence-based management protocols.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Benfell A et al. Outcomes and opportunities: evaluating an unselected cohort of patients with adrenal incidentaloma at a tertiary hospital in New Zealand. Intern Med J. 2026 May 05. doi: 10.1111/imj.70451. PMID: 42085708.

2. Fassnacht M et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42.

3. Mayo-Smith WW et al. Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(8):1038-1044.